

Justification Document for the Selection of a CoRAP Substance

Substance Name (public name): 1,4-diisopropylbenzene

EC Number: 202-826-9

CAS Number: 100-18-5

Authority: BG MSCA

Date: 22/03/2016

Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

Contents

1 IDENTITY OF THE SUBSTANCE	3
1.1 Other identifiers of the substance	3
OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	5
3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)	6
3.1 Classification	6
3.1.1 Harmonised Classification in Annex VI of the CLP	6
3.1.2 Self classification	6
3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP	6
4 INFORMATION ON (AGGREGATED) TONNAGE AND USES	7
4.1 Tonnage and registration status	7
4.2 Overview of uses	7
5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP	
SUBSTANCE	8
5.1. Legal basis for the proposal	8
5.2. Selection criteria met (why the substance qualifies for being in CoRAP)	8
5.3 Initial grounds for concern to be clarified under Substance Evaluation	8
5.4 Preliminary indication of information that may need to be requested to cla	rify
the concern	10
5.5 Potential follow-up and link to risk management	10

1 IDENTITY OF THE SUBSTANCE

1.1 Other identifiers of the substance

Table: Other Substance identifiers

	EC name (public	c).	1,4-diisopropylbenzene		
			Z/T diisopropyibelize		
	IUPAC name (p	ublic):	1,4-di(propan-2-yl)benzene		
	Index number i Regulation:	n Annex VI of the CLP			
	Molecular form	ula:	C ₁₂ H ₁₈		
	Molecular weigl range:	ht or molecular weight	162.2713		
	Synonyms:		p-Diisopropylbenzene		
Туре	of substance	☑ Mono-constituent	☐ Multi-constituent	□ UVCB	
Structural formula:					
H_3C CH_3					

Other relevant information about substance composition

1.2 Similar substances/grouping possibilities

The diisopropylbenzene (DIPB) category consists of a group of three chemicals consisting of CAS No. 99-62-7, 100-18-5, and 25321-09-9. The two first members of the category, meta-DIPB (99-62-7) and para-DIPB (100-18-5), are pure isomers while the third member (xDIPB) is a Class II chemical consisting of a mixture of all three ortho-, meta-, and para-DIPB isomers.

xDIPB may contain small amounts of cumene and other aromatic hydrocarbon impurities¹. The ortho-DIPB is not registered under REACH and no information is available. The three DIPB, CAS No. 99-62-7 (meta-DIPB), 100-18-5 (para-DIPB) and 577-55-9 (ortho-DIPB) that constitute the DIPB category are obviously very similar from a structural standpoint as they are all isomers of the same compound and possess nearly identical physical-chemical properties. It has been considered

¹ HPV challenge program, diisopropylbenzene (DIPB) category, test plan, October 3, 2002.

within the HPV Program assessment that data from studies conducted on the mixture itself (xDIPB) and each of the individual isomers could be used interchangeably in the evaluation of their environmental fate, ecotoxicity, and mammalian toxicity potentials. The impurities reported in the composition of xDIPB are not taken into account in the frame of the manual screening but may be relevant for further assessment.

The substance diisopropylbenzene (xDIPB), consisiting of three chemicals with CAS No. 99-62-7 (meta-DIPB), 100-18-5 (para-DIPB) and 577-55-9 (ortho-DIPB) was manually screened by France on 27 May 2014 and is included in CoRAP 2015-2017 for SEV in 2017.

The registered substance 1,4-diisopropylbenzene (para-DIPB, CAS No. 100-18-5) is the substance of interest for this justification document and is structurally similar to 1,3-diisopropylbenzene (meta-DIPB, CAS No. 99-62-7) and diisopropylbenzene (xDIPB) mixture (CAS No. 25321-09-9).

Table 1: Similar substances, category approach

EC name	EC and CAS numbers	Structural formula	Molecular formula	Molecular weight
Diisopropylbenzene (xDIBP, mixture of par-, ortho- and meta-DIBP)	EC: 246-835-6 CAS: 25321-09-9	H ₃ C CH ₃ CH ₃	C ₁₂ H ₁₈	162,27
1,4-diisopropylbenzene (para-DIBP)	EC: 202-826-9 CAS: 100-18-5	H ₃ C CH ₃	C ₁₂ H ₁₈	162,27
1,3-diisopropylbenzene (meta-DIBP)	EC: 202-773-1 CAS: 99-62-7	H ₃ C CH ₃ CH ₃	C ₁₂ H ₁₈	162,27
1,2-bis(1- methylethyl)benzene (ortho-DIPB)	EC: 209-412-7 CAS: 577-55-9	H ₃ C CH ₃	C ₁₂ H ₁₈	162,27

2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

Table: Completed or ongoing processes

RMOA		\square Risk Management Option Analysis (RMOA)		
REACH Processes	Evaluation	☐ Compliance check, Final decision		
		□ Testing proposal		
		☐ CoRAP and Substance Evaluation		
	Authorisation	☐ Candidate List		
		☐ Annex XIV		
Restri -ction		☐ Annex XVII²		
Harmonise d C&L	☐ Annex VI (CLP) (see section 3.1)			
sses other lation		☐ Plant Protection Products Regulation		
Processes under other EU legislation	Regulation (EC) No 1107/2009 Biocidal Product Regulation Regulation (EU) 528/2012 and amendments			
uus		☐ Dangerous substances Directive Directive 67/548/EEC (NONS)		
Previor	☐ Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS)			
EP) holm ntion iPs		☐ Assessment		
(UNEP) Stockholm convention (POPs Protocol)	☐ In relevant Annex			

² Please specify the relevant entry.



Ongoing Testing proposals: under Evaluation based on the registration dossier as submitted (dossier updated on 03 August 2015).

- 1. Sub-chronic toxicity (90-day) study: oral route (OECD 408: Repeated Dose 90-Day Oral Toxicity in Rodents), testing proposed with CAS no. 99-62-7. Deadline for submitting information: the study to be conducted in due course following approval by ECHA.
- Combined Repeated dose toxicity study:oral route (OECD 422: Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test), testing proposed with CAS no. 100-18-5. Deadline for submitting information: the study will begin August-September 2015, and a final report will be available by 1st quarter 2016.
- 3. Reproductive toxicity (prenatal developmental toxicity) study (OECD 414: Prenatal Developmental Toxicity Study), testing proposed with CAS no. 99-62-7. Deadline for submitting information: the study to be conducted in due course following approval by ECHA.

Source: ECHA WEB site, 05/10/2015.

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

There is no harmonised classification of the substance under Annex VI of the CLP.

3.1.2 Self classification

• In the registration:

Registrant self-classifies the substance as:

Skin Irrit. 2, H315 Causes skin irritation.

 The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Acute Tox. 4,
Acute Tox. 4,
Skin Irrit. 2,
Eye Irrit. 2
Acute Tox. 4,
STOT SE 3,
Repr. 2,
Aquatic Acute 1,
Aquatic Chronic 1,
Aquatic Chronic 4,
Acute Tox. 4,
B302: Harmful if swallowed.
H312: Harmful in contact with skin.
H315 Causes skin irritation.
H319: Causes serious eye irritation.
H332: Harmful if inhaled.
H335: May cause respiratory irritation.
H361: Suspected of damaging fertility or the unborn child.
H400: Very toxic to aquatic life
H410: Very toxic to aquatic life with long lasting effects.
H413: May cause long lasting harmful effects to aquatic life.

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

No harmonized classification is proposed for this substance.

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES³

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site					
□ Full registration(s) (Art. 10)		\square Intermediate registration(s) (Art. 17 and/or 18)			
Tonnage band (as per dissemination site)					
□ 1 – 10 tpa ⊠ 10		☑ 10 – 100 tpa		□ 100 – 1000 tpa	
□ 1000 - 10,000 tpa □ 10		□ 10,000 - 100,000 tpa		☐ 100,000 - 1,000,000 tpa	
☐ 1,000,000 - 10,000,000 tpa	□ 10, tpa	☐ 10,000,000 - 100,000,000 tpa		□ > 100,000,000 tpa	
□ <1 >+ tpa)+ ; 100+ ; 10	,000+ tpa)	☐ Confidential		
Joint Submission.					
4.2 Overview of uses					
Table: UsesPart 1:					
		\boxtimes		☐ Article	⊠ Closed
	idustrial se	Professional use	Consumer use	service life	system
The identified uses of the substance are:					
Uses at industrial sites:Industrial uses as Process Solvent for Print Inks					
Use as an Intermediate Use by Professional Westerner					
Uses by Professional Workers:					
Professional Laboratory Use					

EC no 202-826-9 MSCA - BG Page 7 of 10

 $^{^{3}}$ Please provide here the date when the dissemination site was accessed.

SUBSTANCE 5.1. Legal basis for the proposal ☑ Article 44(2) (refined prioritisation criteria for substance evaluation) ☐ Article 45(5) (Member State priority) **5.2. Selection criteria met** (why the substance qualifies for being in CoRAP) ☑ Fulfils criteria as CMR/ Suspected CMR ☐ Fulfils criteria as Sensitiser/ Suspected sensitiser ☐ Fulfils criteria as potential endocrine disrupter ☑ Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB \Box Fulfils criteria high (aggregated) tonnage (*tpa* > 1000) ☐ Fulfils MS's (national) priorities 5.3 Initial grounds for concern to be clarified under Substance **Evaluation** Hazard based concerns **CMR** Suspected CMR ☐ Potential endocrine disruptor \square C \square M \boxtimes R \Box C \Box M \Box R ☐ Sensitiser ☐ Suspected Sensitiser ☐ Other (please specify below) Suspected PBT/vPvB¹ ☐ PBT/vPvB Exposure/risk based concerns ☐ Exposure of sensitive ☐ Wi e dispersive use ☐ Consumer use populations ☐ Exposure of ☐ Cumulative exposure environment ☐ High RCR \square High (aggregated) tonnage ☐ Other (please specify below)

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP

Regarding the suspected PBT/vPvB concern

The registered substance is not readily degradable according to the available data in the dossier. However, the biodegradation data are considered insufficient and not fully satisfactory to assess P/vP properties. The registrant stated that no conclusion can be reached based on available information; however no indication of a testing proposal is provided in the dossier. Based on estimated and experimental data, the substance fulfils the screening criteria for P and leaves the potential for vP. There is a lack of data to fully assess P or vP. Further assessment is considered needed on the P/vP criterion.

Based on the provided experimental Log Kow of 5.23, the substance fulfils the B criterion on screening. The substance is considered stable in the aquatic compartment. Based on a provided read-across bioaccumulation study, the B criterion is clearly fulfilled (with BCF>2000<5000) on screening. No bioaccumulation, biota-sediment accumulation, and biomagnification factors (BAF, BSAF, BMF) are provided in the registration dossier. Based on the bioaccumulation estimated data for BCF, the substace indicate a potential for vB (>5000). Therefore, the substance clearly fulfills the B criterion and is potentially vB on screening based on experimental and estimated data. Further assessment is considered needed on the B/vB criterion.

The substance is presented by the registrant to not fulfill the T criterion, but further information is necessary to conclude on the T properties in the context of the PBT assessment. Based on the estimated chronic aquatic toxicity data, the substance is to be considered as fulfilling the T criterion on screening. Depending on the P/vP and B/vB outcome, the aquatic chronic toxicity could be further investigated. Moreover the notifications of classification as aquatic chronic 1 (H410) should be further assessed.

Regarding the Suspected Reproductive Toxicity concern

If the substance is included in the CoRAP list because of its PBT properties, the proposed studies should be evaluated in order to clarify the concern associated with the notified Repr. 2 classification. In addition, if reproductive toxicity is verified, workplace exposure scenarios and risk characterization taking into account Council Directive 92/85/EEC and Directive 98/24/EC ("Chemical Agents Directive") would be needed.

Conclusion:

The substance to be included in the CoRAP 2016-2018 list for evaluation in 2018.

References:

- EPIWEB 4.1 (US EPA, Nov. 2012). Estimation Programs Interface Suite™ for Microsoft® Windows, v 4.11 or insert version used]. United States Environmental Protection Agency, Washington, DC, USA.
- 2. PBT profiler (http://www.pbtprofiler.net/): Developed by the Environmental Health Analysis Center under contract to the Office of Chemical Safety and Pollution Prevention , U.S. Environmental Protection Agency Computer Resources Donated by SRC, Inc. Ver 2.000 Last Updated September 4, 2012.
- 3. ECOSAR[™] estimation program (http://www.pbtprofiler.net/ecosarres.asp?I=0&K=4.905), ECOSAR Version 1.11.
- 4. www.echemportal.org, OECD SIDS INITIAL ASSESSMENT PROFILE of 1,4-diisopropylbenzene.
- 5. http://webnet.oecd.org/CCRWEB/ChemicalDetails.aspx?Key=567a7cdf-4925-4ae3-90da-c8c35a211a30&Idx=0

5.4 Preliminary indication of information that may need to be requested to clarify the concern					
☐ Information on toxicological properties	\square Information on physico-chemical properties				
☑ Infomation on fate and behaviour	☑ Information on exposure				
☑Information on ecotoxicological properties	☐ Information on uses				
☐ Information ED potential	☐ Other (provide further details below)				
Suspected PBT or vP/VB concern					
Additional information is required to conclude	on PBT or vP/vB properties.				
Depending on the P/vP and B/vB outcome, the aquatic chronic toxicity (on other species than aquatic invertebrates) might need to be investigated further to conclude on the T properties in the context of the PBT assessment.					
Suspected Reproductive Toxicity concern					
If the substance is included in the CoRAP list because of its PBT properties, the proposed studies should be evaluated in order to clarify the concern associated with the notified Repr. 2 classification. In addition, if reproductive toxicity is verified, workplace exposure scenarios and risk characterization taking into account Council Directive 92/85/EEC and Directive 98/24/EC ("Chemical Agents Directive") should be needed.					
Conclusion:					
The substance to be included in the CoRAP 2016-2018 list for evaluation for 2018.					
5.5 Potential follow-up and link to risk management					
☐ Harmonised C&L ☐ Restriction ☐	Authorisation				
If the substance is identified/evaluated as a PBT/vPvB substance, an analysis of risk management options (RMOA) will be carried out, taking into account information on use and exposure. Potential options are the inclusion in the Candidate List with or without Authorisation, but also Restriction.					